Eur Rev Med Pharmacol Sci 2021; 25 (13): 4441-4442
DOI: 10.26355/eurrev_202107_26230

Treatment options after regorafenib failure in metastatic colorectal cancer

M. Berretta, F. Fiorica, V. Quagliariello, M.M. Laterza, G. Facchini, M. Montopoli

Department of Clinical and Experimental Medicine, University of Messina, Messina Italy. berrettama@gmail.com

Free PDF Download

To cite this article

M. Berretta, F. Fiorica, V. Quagliariello, M.M. Laterza, G. Facchini, M. Montopoli
Treatment options after regorafenib failure in metastatic colorectal cancer

Eur Rev Med Pharmacol Sci
Year: 2021
Vol. 25 - N. 13
Pages: 4441-4442
DOI: 10.26355/eurrev_202107_26230

Keywords Related articles:

  1. Treatment options after regorafenib failure in metastatic colorectal cancer
  2. Association between bevacizumab-related chemotherapy regimens and serum vascular endothelial growth factor-A165b level in patients with metastatic colorectal cancer
  3. Association between bevacizumab-related chemotherapy regimens and serum vascular endothelial growth factor-A165b level in patients with metastatic colorectal cancer
  4. Docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer: a meta-analysis
  5. The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: a preliminary report